Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

DB:RIG2 Stock Report

Market Cap: €4.6b

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Valuation

Is RIG2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RIG2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RIG2 (€25.12) is trading below our estimate of fair value (€70.14)

Significantly Below Fair Value: RIG2 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RIG2?

Key metric: As RIG2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RIG2. This is calculated by dividing RIG2's market cap by their current earnings.
What is RIG2's PE Ratio?
PE Ratio9x
EarningsFt211.64b
Market CapFt1.91t

Price to Earnings Ratio vs Peers

How does RIG2's PE Ratio compare to its peers?

The above table shows the PE ratio for RIG2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.7x
DMP Dermapharm Holding
22.9x17.0%€2.0b
MRK Merck KGaA
22.6x11.1%€59.9b
PSG PharmaSGP Holding
15.6x13.6%€287.8m
2FJ0 Pierrel
29.9xn/a€92.8m
RIG2 Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
9x14.2%€1.9t

Price-To-Earnings vs Peers: RIG2 is good value based on its Price-To-Earnings Ratio (9x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does RIG2's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
RIG2 9.0xIndustry Avg. 19.5xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RIG2 is good value based on its Price-To-Earnings Ratio (9x) compared to the European Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is RIG2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RIG2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9x
Fair PE Ratio17.5x

Price-To-Earnings vs Fair Ratio: RIG2 is good value based on its Price-To-Earnings Ratio (9x) compared to the estimated Fair Price-To-Earnings Ratio (17.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RIG2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€25.12
€29.63
+17.9%
9.6%€32.19€23.01n/a9
Dec ’25€25.40
€29.31
+15.4%
9.5%€31.96€22.85n/a9
Nov ’25€26.80
€30.02
+12.0%
9.8%€33.12€23.81n/a9
Oct ’25€27.38
€30.02
+9.6%
9.8%€33.12€23.81n/a9
Sep ’25€27.46
€29.78
+8.5%
9.7%€33.29€23.93n/a9
Aug ’25€26.10
€29.73
+13.9%
10.7%€33.76€23.77n/a9
Jul ’25€24.70
€29.73
+20.4%
10.7%€33.76€23.77n/a9
Jun ’25€24.00
€30.73
+28.0%
10.7%€34.90€24.57n/a9
May ’25€23.52
€29.70
+26.3%
9.9%€34.10€24.01n/a9
Apr ’25€23.20
€29.17
+25.7%
10.4%€33.94€23.90n/a9
Mar ’25€24.34
€28.76
+18.2%
10.9%€34.01€23.95n/a9
Feb ’25€24.68
€28.42
+15.2%
10.2%€33.86€24.59n/a9
Jan ’25€22.56
€28.28
+25.4%
8.0%€31.92€25.10n/a9
Dec ’24€22.60
€28.28
+25.1%
8.0%€31.92€25.10€25.409
Nov ’24€22.06
€27.06
+22.7%
9.1%€32.34€24.22€26.809
Oct ’24€22.64
€27.21
+20.2%
10.0%€32.88€24.17€27.389
Sep ’24€23.20
€27.21
+17.3%
10.0%€32.88€24.17€27.469
Aug ’24€22.64
€27.17
+20.0%
11.2%€33.55€23.70€26.109
Jul ’24€22.62
€27.17
+20.1%
11.2%€33.55€23.70€24.709
Jun ’24€23.02
€27.17
+18.0%
11.2%€33.55€23.70€24.009
May ’24€21.70
€26.93
+24.1%
11.8%€33.51€22.87€23.529
Apr ’24€18.74
€26.75
+42.7%
13.0%€33.68€22.63€23.208
Mar ’24€19.53
€28.98
+48.4%
14.4%€36.99€24.47€24.348
Feb ’24€20.46
€27.46
+34.2%
15.4%€35.43€22.32€24.688
Jan ’24€20.30
€26.95
+32.7%
16.9%€34.82€21.84€22.568
Dec ’23€20.38
€25.58
+25.5%
16.0%€34.17€21.44€22.607

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 19:06
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Simon MatherBarclays
Samuel EnglandBerenberg
Victoria LambertBerenberg